Skip to Main content Skip to Navigation

Optimisation médico-économique des stratégies d'utilisation des examens TEP/TDM en imagerie oncologique

Abstract : Positron emission tomography coupled with computed tomography (PET/CT) devices are essential pathways in oncology. Many studies have reported the performances of the various radiopharmaceutical drugs (RPD) used for PET/CT imaging in many cancers. The rise of PET/CT remains slowed down in France for economic reasons. However, the difference between the cost of a PET/CT examination, compared to that of another modern imaging routinely used in the same indication, is not so obvious once considered the impact on decision making and the costs avoided by the revision of erroneous or incomplete diagnoses. Nonetheless, if all PET/CT examinations are currently reimbursed in the same way regardless of the RPD used, thus making their cost identical from the health insurance perspective, their production costs for the hospital vary and should be considered according to the frequency of the indication of the examination.We compared several imaging strategies for prostate cancer imaging by analyzing the data acquired during the French prospective multicenter FLUPROSTIC study, which included two RPD for PET imaging: 18F-flurocholine (FCH) and 18F-sodium fluoride (NaF), FCH being twice more costly for the hospital than NaF.The analysis of the impact of each imaging strategy on decision making, based on dedicated questionnaires completed by the referring clinicians, demonstrated that FCH PET/CT was the imaging modality that had the highest impact, especially for patients presenting with first biochemical recurrence.The cost-utility analysis, carried out from the health insurance perspective for patients with first biochemical recurrence of prostate cancer over a "lifetime" time horizon, was based on a model5combining a decision tree integrating the diagnostic performances of imaging and a Markov model simulating the natural history of prostate cancer. This analysis demonstrated that FCH PET/CT, the most accurate imaging modality from a diagnostic point of view, had a 100% probability of being the most cost-effective strategy for willingness to pay thresholds of 3,000€ or 9,000€ per quality-adjusted life year gained if the imaging reading was made by local specialists or experts respectively. From the hospital perspective, the 20% drop in the cost of FCH between 2018 and 2019 had made profitable the production of FCH PET/CT examinations for prostate cancer imaging.PET/CT increases diagnostic accuracy and has an impact on decision making in many cancers. It helps to reduce unnecessary treatments and their potential side effects, to improve the quality of life of patients and to reduce the treatment costs for the health care system. The medico-economic evaluation of RPDs used for PET/CT imaging in oncology, in addition to that of their diagnostic performances, seems essential in order to optimize their use. In France, this evaluation should be made from both perspectives of the health insurance and the hospital. Indeed, the PET/CT production costs can largely vary for the hospital according to the RPD costs and constitute a barrier to its use, even in a frequent indication for which diagnostic performances and impact on decision making are high.
Complete list of metadata
Contributor : Abes Star :  Contact
Submitted on : Saturday, April 3, 2021 - 3:23:10 PM
Last modification on : Thursday, April 15, 2021 - 4:23:05 PM


Version validated by the jury (STAR)


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License


  • HAL Id : tel-03189398, version 1



Mathieu Gauthé. Optimisation médico-économique des stratégies d'utilisation des examens TEP/TDM en imagerie oncologique. Médecine humaine et pathologie. Université de Paris, 2020. Français. ⟨NNT : 2020UNIP7040⟩. ⟨tel-03189398⟩



Record views


Files downloads